AJCP / Meeting AbstrActs neoplasms. As such, we compared patients with myeloid disorders who underwent next-generation sequencing (NGS) to compare the percentage of ring sideroblasts and clinical features when SF3B1 variants were detected. We identified 13 patients with SF3B1 variants; 10 randomly selected patients with myeloid neoplasms lacking SF3B1 mutations were used as controls. SF3B1 variants were identified using a 25-gene panel and interrogated via the Ion Torrent, while ring sideroblasts were quantitated using the aspirate. Age, sex, disease classification, SF3B1 variant type, ring sideroblast percentage, and progression to acute leukemia were recorded for each subject. Among 13 patients with variant SF3B1, the mean age was 73.5 years, 62% were women, and 92.3% were still alive at the time of study. The majority (84.6%) had variants in known SF3B1 "hotspots." Of these 13 patients, nine (69.2%) met World Health Organization criteria for a recognized myeloid neoplasm with ring sideroblasts. Compared to controls, the mean percentage of ring sideroblasts was significantly higher in patients with any SF3B1 variant (31.2% vs 2.7%; P = .0011). Among patients with SF3B1 variants in known hotspots, there was a trend toward higher ring sideroblasts (mean 34.8%) as compared to non-hotspot variants (mean 11.5%), although numbers were too small for statistical comparisons. Subjects with any SF3B1variant and myeloid neoplasm with ring sideroblasts had a lower incidence of high-grade MDS and progression to acute leukemia compared with controls. In summary, SF3B1 variants correlated with an increased number of ring sideroblasts independent of diagnosis. Given their unique attributes, SF3B1-hostspot-positive myeloid neoplasms, particularly those associated with MDS, may ultimately be best characterized as a distinctive entity.
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Evaluation of the Role of pAKT Expression in Epithelial Mesenchymal Transition in Uterine Carcinosarcoma
Amir Momeni Boroujeni, MD, Elham Yousefi, MD, Ning Chen, MD, PhD, Raavi Gupta, MD; SUNY Downstate Medical Center, Brooklyn, NY Objectives: Epithelial-mesenchymal transition (EMT) has been shown to be the underlying mechanism of the morphologic variation of carcinosarcomas. EMT involves loosening of epithelial adhesion structures and transformation of epithelial cells into mesenchymal cells. It is believed that EMT in uterine carcinosarcomas (UCSs) is due to alterations of the AKT-pathway. Increased AKT expression leads to modulation of expression of downstream genes, such as SLUG, leading to cytoskeletal and cell-cell adhesion changes. Loss of E-cadherin expression is the hallmark of EMT. In this study, we investigated the role of AKT in EMT of UCS.
Methods: A total of 33 cases of UCS were selected, and survival data were obtained. Immunohistochemical staining with E-cadherin (EP700Y, 1:200 dilution, RocheVentana) and pAKT (ab8805, 1:350 dilution, Abcam) was performed. Expression pattern of the antibodies was assessed in the epithelial and mesenchymal components of the tumor. Loss of E-cadherin in the mesenchymal component was considered epithelial mesenchymal transition. Staining of <20% cells was considered negative. Survival data were compared using cox regression to determine the prognostic significance of AKT expression. Results: Of 33 cases, 28 showed loss of E-cadherin expression in mesenchymal component. Fourteen of 28 cases (50%) showed increased expression of pAKT in the mesenchymal component. Three of 28 cases (10.7%) showed positivity of both components, and in 10/28 cases (35.7%), both components were negative for pAKT. One case showed positive pAKT staining in the epithelial component and negative staining in the mesenchymal component. Survival analysis showed no prognostic effect of AKT expression. Conclusion: AKT pathway is the main mechanism of epithelial mesenchymal transition in UCS. Our results show that AKT pathway alterations drive the EMT in 50% of UCS cases. In other cases, alternative pathways such as RHOA/ROCK pathway should be investigated. The mechanism of EMT appears to have no effect on survival.
EBV and HHV1 Positive CNS Inflammatory Pseudotumor: A Case Report
Christian Salib, MD, Taliya Farooq, MD, George Kleinman, MD; Westchester Medical Center/New York Medical College, Valhalla Inflammatory pseudotumor (IPT) is a rare benign lesion of unknown cause, commonly involving the lung and orbit but found in virtually every body site. IPT was first described in 1954 based on imaging findings that mimicked those of malignant tumors. This rare entity, which consists of mixed inflammatory cells and myofibroblastic spindle cells, is often associated with Epstein-Barr virus (EBV) positivity. Here we are presenting a case of a 56-year-old Hispanic woman with a history of headaches, dizziness, and frequent falls. MRI of the head demonstrated a right temporal lesion with enhancement along the temporal convexity, extending into the insula. A lumbar puncture yielded atypical lymphocytes with increased nuclear to cytoplasmic ratio, irregular nuclear contours, and coarse chromatin. Cerebral spinal fluid flow cytometry revealed a mixed population of cells, including B-cells expressing CD19, CD20, kappa, and lambda. A subsequent open biopsy revealed areas of dense, mixed infiltrates consisting of lymphocytes, histiocytes, plasma cells
